Regards Medicaid managed care coverage of pharmacogenomic testing

Summary

The bill directs Medicaid managed care organizations to cover genetic tests that assess how a patient’s genes affect drug safety and effectiveness when treating depression or anxiety, provided a prescriber orders the test and it meets Medicare local coverage criteria. It also sets limits on prior‑authorization requirements and creates penalties for organizations that fail to follow the new rules.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Topics

Share